Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02495857 · ClinicalTrials.gov registry record · NA
A Study of Hyaluronate Injectable Viscosupplement for Treatment of Osteoarthritis of the Knee
A NA study, sponsored by Actavis.
- Completed
- Registry status
- NA
- Development phase
- 599
- Enrollment target
NCT02495857: Completed NA study, sponsored by Actavis.
NCT02495857 is a NA study that has completed, run by Actavis. The registered enrollment target is 599 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02495857, a NA study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- NA
- Development phase
- 599 participants
- Enrollment target
Study Summary
The study is a prospective, multi-center, randomized, three-arm, parallel group, clinical study to evaluate the superiority of 3 weekly intra-articular (IA) doses of 2 mL of Investigational hyaluronate as compared to placebo injected into the target knee for the treatment of pain in subjects with Osteoarthritis (OA).The safety and effectiveness of the investigational product will also be compared with Euflexxa.
Primary Outcome
The primary effectiveness endpoint was the change from Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC®) pain score in the target knee at Week 26.The validated WOMAC was used to assess pain, stiffness, and physical function of the target knee.The range of pain score was 0 to 500 mm with higher scores for worse pain.
Interventions
- DEVICE Placebo
- DEVICE Hyaluronate Injectable Viscosupplement
- DEVICE Euflexxa IA injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2015-08-15 |
| Est. Completion | 2016-12-05 |
| Phase | NA |
What the finished NCT02495857 record still lists
NCT02495857 is an interventional study that assigns participants to a tested intervention. The registered 599 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02495857 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02495857 about?
NCT02495857 is a clinical study titled "A Study of Hyaluronate Injectable Viscosupplement for Treatment of Osteoarthritis of the Knee". The study is a prospective, multi-center, randomized, three-arm, parallel group, clinical study to evaluate the superiority of 3 weekly intra-articular (IA) doses of 2 mL of Investigational hyaluronate as compared to placebo injected into the target knee for the treatment of pain in subjects with Os...
What is the current status of trial NCT02495857?
This trial is currently completed. It is a NA study. The enrollment target is 599 participants. The study started on 2015-08-15. Estimated completion is 2016-12-05.
What interventions are being tested in trial NCT02495857?
The interventions under investigation include: Placebo (DEVICE), Hyaluronate Injectable Viscosupplement (DEVICE), Euflexxa IA injection (DEVICE).
Who is sponsoring clinical trial NCT02495857?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02495857's enrollment target sits among peer trials
599 174th of 2000 higher than 1,827 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06875973 · 599 participants · Phase 3
Pelacarsen Roll-over Extension Program
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI